JP Morgan Chase’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-100
| Closed | -$66 | – | 7802 |
|
|
2024
Q2 | $66 | Hold |
100
| – | – | ﹤0.01% | 6971 |
|
|
2024
Q1 | $61 | Buy |
100
+11
| +12% | +$7 | ﹤0.01% | 6994 |
|
|
2023
Q4 | $52 | Hold |
89
| – | – | ﹤0.01% | 7203 |
|
|
2023
Q3 | $59 | Hold |
89
| – | – | ﹤0.01% | 6975 |
|
|
2023
Q2 | $293 | Sell |
89
-11,981
| -99% | -$36.2K | ﹤0.01% | 6594 |
|
|
2023
Q1 | $110K | Buy |
12,070
+3,975
| +49% | +$56.3K | ﹤0.01% | 5381 |
|
|
2022
Q4 | $95K | Buy |
8,095
+4,505
| +125% | +$79.5K | ﹤0.01% | 5368 |
|
|
2022
Q3 | $76K | Buy |
3,590
+71
| +2% | +$1.91K | ﹤0.01% | 5409 |
|
|
2022
Q2 | $85K | Sell |
3,519
-409
| -10% | -$13.9K | ﹤0.01% | 5490 |
|
|
2022
Q1 | $196K | Buy |
3,928
+1,447
| +58% | +$71.5K | ﹤0.01% | 5206 |
|
|
2021
Q4 | $174K | Sell |
2,481
-4,590
| -65% | -$387K | ﹤0.01% | 5430 |
|
|
2021
Q3 | $659K | Buy |
7,071
+4,631
| +190% | +$440K | ﹤0.01% | 4570 |
|
|
2021
Q2 | $245K | Buy |
2,440
+139
| +6% | +$13.5K | ﹤0.01% | 5132 |
|
|
2021
Q1 | $214K | Sell |
2,301
-383
| -14% | -$38.8K | ﹤0.01% | 5123 |
|
|
2020
Q4 | $221K | Buy |
2,684
+547
| +26% | +$46.6K | ﹤0.01% | 4778 |
|
|
2020
Q3 | $191K | Sell |
2,137
-3,077
| -59% | -$359K | ﹤0.01% | 4384 |
|
|
2020
Q2 | $485K | Buy |
5,214
+3,579
| +219% | +$197K | ﹤0.01% | 3862 |
|
|
2020
Q1 | $46K | Sell |
1,635
-5,045
| -76% | -$196K | ﹤0.01% | 4752 |
|
|
2019
Q4 | $277K | Buy |
6,680
+5,763
| +628% | +$126K | ﹤0.01% | 4547 |
|
|
2019
Q3 | $13K | Buy |
917
+149
| +19% | +$3.12K | ﹤0.01% | 5479 |
|
|
2019
Q2 | $25K | Buy |
+768
| New | +$41.6K | ﹤0.01% | 5405 |
|
|
2018
Q3 | – | Sell |
-11
| Closed | -$1K | – | 5875 |
|
|
2018
Q2 | $1K | Sell |
11
-637
| -98% | -$61.5K | ﹤0.01% | 5500 |
|
|
2018
Q1 | $68K | Sell |
648
-1,966
| -75% | -$235K | ﹤0.01% | 4715 |
|
|
2017
Q4 | $335K | Buy |
+2,614
| New | +$321K | ﹤0.01% | 4246 |
|
JP Morgan Chase's VBIV Position: Q3 2024 in Review
JP Morgan Chase sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q3 2024, closing a stake of 100 shares — an estimated $66 sold.
JP Morgan Chase first reported a position in VBIV in Q4 2017 and held it in 24 quarters. The position peaked at $659K in Q3 2021. 1 fund tracked by Wall St. Rank holds VBIV as of Q3 2024.
- JP Morgan Chase reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q3 2024 after selling out during the quarter.
- JP Morgan Chase sold 100 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q3 2024, an estimated $66.
- JP Morgan Chase first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q4 2017 and held it in 24 quarters.
- JP Morgan Chase's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $659K in Q3 2021.
- 1 fund tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q3 2024.
Based on JP Morgan Chase's 13F filing for Q3 2024, filed 8 Nov 2024.